CJC-1295 is a synthetic peptide developed to induce growth hormone and insulin growth factor levels, with a similar mechanism of action as the growth hormone-releasing hormone (GHRH) in its function. Due to their suggested similar functions, CJC-1295 may support sleep cycles, muscle growth, and fat loss.
According to an article in The Journal of Clinical Endocrinology & Metabolism , the researchers suggest the peptide may potentially be used as a therapeutic agent. As more studies were conducted, researchers reported  that this peptide may offer a potential positive effect on physical performance.
CJC-1295 Peptide Safety Profile
Initial studies, including a study conducted in 2005 , reported that when test subjects were administered the recommended dose, the peptide was well-tolerated and no adverse reactions were exhibited in a research setting. There have been reports of minor side effects, particularly at the administration site. Some of these side effects may include:
- Soreness and skin sensitivity
- Flushing of the skin
- Symptoms similar to the flu
CJC-1295 with DAC
Researchers have combined CJC-1295 peptide with a biological complex called DAC to determine if the addition of DAC may improve efficacy or longevity of the peptide solution. The blend has undergone heavy lab testing. DAC, an acronym for Drug Affinity Complex, is an all new biochemical complex that, when bound with peptides, may offer a potential advantage to the absorption and duration of peptides. Much of the lab testing of this new peptide blend is performed on rodents, but some studies have also tested the substance on canines.
Half-Life of CJC-1295
When administered on rats, research suggested  that DAC, when combined with CJC-1295 peptide, appeared to significantly increase the short half-life of CJC-1295 alone from an average of 30 minutes to about 7-8 days. To clarify, the term “half-life” is how long it takes for the body’s concentration of a substance, drug or compound to be cut in half.
CJC 1295 with DAC vs No DAC
Many researchers are trepidatious in the use of CJC-1295 or CJC-1295 with DAC. Hesitation is to be expected. Initial research suggests the CJC-1295 peptide bound with DAC doesn’t appear to alter effects in test subjects. The primary difference exhibited was CJC-1295 without DAC would not live and act as long as it would with DAC. It may be inferred that the test subjects would require less frequent dosages. As a result, researchers may potentially save on research costs.
CJC-1295 Ipamorelin Blend
Similar to CJC-1295, Ipamorelin is a peptide that is considered to a growth hormone releasing peptide, with a reported increasingly precise activation. By stimulating the pituitary gland, the Ipamorelin peptide may induce the secretion of the growth hormone – leading to possible results in test subjects such as weight loss and lean muscle growth.
Since CJC-1295 and Ipamorelin are similar peptides in their composition, proposed function and effect, researchers have bonded the peptides together to determine in the combination may increase weight loss, improve lean muscle growth, enhance cognitive health, or improve the immune system. Due to the suggested function of these two peptides, their combination may produce an increased, consistent release of the human growth hormone. Such a release could exhibit the following:
- Anti-aging properties
- An increase in collagen and elastin levels (vital for skin health)
- Boosted lean muscle growth and repair
- Accelerated injury recovery, especially joint injuries
- Increased fat burn and weight loss
- Cognitive enhancements, especially in subjects with neurological diseases
It must be clear that none of the peptides listed above are approved for human use, their use has only been investigated in carefully curated research environments on animal models, and is available here strictly for research purposes.
For research supplies, review a selection of CJC-1295 with DAC, and Ipamorelin, and CJC-1295 Ipamorelin blend
NOTE: The information found on this website and within this article is intended for educational or informational purposes only. Some or all of the content in these articles are not substantiated by a medical professional and may be based on the opinions of the writer who may not be a medical or accredited professional. Not intended for personal or human use. Please review our Terms and Conditions before purchasing.
Dr. Marinov (MD, Ph.D.) is a researcher and chief assistant professor in Preventative Medicine & Public Health. Prior to his professorship, Dr. Marinov practiced preventative, evidence-based medicine with an emphasis on Nutrition and Dietetics. He is widely published in international peer-reviewed scientific journals and specializes in peptide therapy research.